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Abstract
Background: Systemic Sclerosis (SSc) is characterized by skin thickening, fibrosis and vascular obliteration. The onset and course are 
heterogeneous. Prominent features include autoimmunity, inflammation and vascular damage.
Aim of study: To measure the level of serum Anti-Annexin V antibodies in SSc patients and to study its significance in relation to 
vascular damage in these patients.
Patients and methods: Twenty patients with SSc (12 with diffuse SSc and 8 with the limited form) and 10 healthy age and sex matched 
volunteers as controls were all subjected to routine laboratory testing and immunological profiling including antinuclear, anti-Scl-70, 
anticentomere, anticardiolipin antibodies and anti-annexin V antibodies titres. Vascular damage was assessed by clinical examination 
and assessment of the disease activity score, nailfold capillaroscopy and colour flow Doppler of the renal arteries; Doppler echocardiog-
raphy was used for assessing pulmonary hypertension.
Results: Anti-annexin V antibodies were detected in 75% of patients. Comparisons between anti-annexin V in diffuse and limited 
  subgroups showed no significance; however a statistically significant positive correlation was found between Anti-annexin V titre 
and the degree of vascular damage in SSc patients. Anti-annexin V increased significantly in patients with severe vascular damage 
in   comparison with those less affected (15.3 ± 6.6 vs. 11.25 ± 3.6, P , 0.05). A significant positive correlation was found between 
  Anti-annexin V titre and both the ACL titre (r = 0.79, P , 0.001) and the resistive index of the main renal artery (r = 0.42, P , 0.05).
Conclusion: Anti-annexin V antibodies were significantly present in sera of patients with SSc. Patients with more severe forms of 
  vascular damage had higher titres of these antibodies. Anti-annexin V antibodies are a sensitive predictor of vascular damage in SSc and 
could serve as a useful parameter in discriminating patients with a higher risk of vascular affection from those without.
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ORIGINAL RESEARCHIntroduction
Systemic sclerosis (SSc), a generalized disorder of 
connective tissue, is characterized clinically by skin 
thickening,  progressive  fibrosis  and  vascular  oblit-
eration that mostly involves the skin, gastrointestinal 
tract, lungs, heart and kidneys. The onset and course of 
the disease is heterogeneous. The prominent   features 
of the disease include autoimmunity, inflammation 
and vascular damage.1
Patients with SSc can be classified into two distinct 
clinical subsets, diffuse and limited, with different 
patterns of skin and internal organ involvement and 
autoantibody  production.  Raynaud’s  phenomenon 
(RP) is a hallmark of the disease. Skin induration and 
internal organ dysfunction are also common features. 
Pulmonary involvement is second in frequency only 
to esophageal involvement as a visceral complication 
of SSc. Interstitial lung disease and pulmonary vas-
cular disease, particularly pulmonary arterial hyper-
tension, are the most commonly encountered types of 
pulmonary involvement in SSc.2
Clinical evaluation and laboratory testing, along with 
pulmonary function tests, Doppler echocardiography 
and high-resolution computed tomography of the chest 
are useful diagnostic tools in establishing a diagnosis in 
SSc patients and detecting visceral involvement. Nail-
fold capillaroscopy (NFC) represents the best method 
for analyzing microvascular damage in SSc.3
Annexin  V,  a  member  of  the  lipocortin  fam-
ily,  is  expressed  within  various  cells,  including 
  nucleoli. Many of these proteins are target mole-
cules for autoantibodies generated in connective tis-
sue diseases, especially in scleroderma and overlap 
  syndromes. Annexin V inhibits prothrombin activa-
tion and is able to prevent thrombus formation under 
normal venous and arterial blood flow conditions. 
Antibodies to Annexin V have been identified in asso-
ciation with several pathological conditions, such as 
fetal loss, and venous and/or arterial thrombosis in 
Systemic lupus erythematosus patients, as well as 
digital ischemia and gangrene in SSc; however, their 
true pathogenic role remains to be proven.4,5
Aim of the study
The aim of this study was to measure the level of 
serum Anti-Annexin  V  antibodies  in  patients  with 
SSc and to study their significance in relation to vas-
cular damage in these patients.
patients and Methods
This  study  was  conducted  on  20  patients,  diag-
nosed with SSc according to the American College 
of Rheumatology classification criteria.6 They were 
attending the rheumatology outpatient clinic and the 
inpatient departments of internal medicine and chest 
in Ain  Shams  University  Hospital.  Informed  con-
sents were obtained from the patients and the study 
was approved by the Ain Shams Medical ethics com-
mittee. Ten healthy age and sex matched volunteers 
were included as a control group. All patients and 
controls were subjected to the following full history 
taking  and  thorough  clinical  examination,  which 
included an assessment of their SSc disease activ-
ity index score which included the identification of 
11 independent variables predictive of disease activ-
ity in SSc:
•  Severity of RP and severity of shortness of breath 
in the past week, both measured on a numerical 
rating scale ranging from 0–10.
•  Average number of episodes of RP per week, in 
the past month.
•  Worsening of scleroderma in the past month.
•  Pulse rate per minute.
•  Presence of basilar crackles.
•  Modified Rodnan skin score ranging from 0–51.
•  Swollen joint count ranging from 0–28.
•  Weight loss in the past year.
•  Hematocrit value.
•  Forced  vital  capacity  measured  as  percent 
predicted.7,8
Laboratory investigations
Routine  laboratory  testing  included  a  complete 
blood  count,  and  erythrocyte  sedimentation  rate 
(ESR) and kidney function tests (blood urea nitro-
gen and serum creatinine). Immunological tests for 
antinuclear  antibody  (ANA)  and  anticentromere 
antibodies  (ACA)  was  performed  by  the    indirect 
immunofluorescene  technique.  AntiScl-70  (anti-
topoisomerase antibodies) and anticardiolipin anti-
bodies (ACA: IgG and IgM) were tested using the 
ELISA  technique.  The  anti-annexin  V  antibodies 
titre used the zyMUTEST anti-Annexin IgG ELISA 
kit. [Hyphen-BioMed, France.]: to measure the IgG 
isotype of auto-antibodies to annexin V in human 
serum.
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The  zyMUTEST  anti-annexin V  IgG  ELISA  uses 
a highly purified human recombinant annexin V for 
isolating the auto-antibody to annexin V. A diluted 
serum is added to an annexin V-coated microtest well. 
If autoantibodies to annexin V are present, they bind 
to the immobilized annexin V. Following washing, 
bound auto-antibodies of the IgG isotype are revealed 
with a goat anti-human-IgG (FC gamma specific) per-
oxidase conjugate. Following another washing step, 
the peroxidase substrate tetramethylbenzidine (TMB) 
is added to the microtest well in the presence of hydro-
gen peroxide (H2O2) and the subsequent enzymatic 
reaction yields a solution with a blue colour. Addition 
of sulphuric acid stops the reaction and turns the solu-
tion color to yellow. The intensity of the colour devel-
oped is directly proportional to the amount of IgG 
isotype anti-annexin V autoantibodies in the sample.
Sample collection and storage
Blood samples were allowed to clot for 30 minutes at 
room temperature and centrifuged for 10 minutes at 
5000 rpm. The serum was then collected in aliquots 
and stored at −20 °C.
Interpretation of the results
Results  are  expressed  according  to  the  A450  val-
ues  obtained  for  samples  and  controls,  using  the 
calibration  curve.  Results  are  expressed  in  units 
relative  to  the  calibrator  (AU/mL)  as  follows: 
negative ,10 AU/mL, ‘grey zone’ 10–20 AU/mL, 
low    positive  $20–,50AU/mL,  moderate  positive 
$50–,100AU/mL and high positive $100 AU/mL.
Widefield nailfold capillaroscopy
Examination was done by means of a Leica Wild M3z 
stereomicroscope  (Leica  AG,  CH-9435  Heebrugg, 
Switzerland). All fingers were examined and the dis-
tal end of the capillaries was evaluated as regards 
morphology, devascularization and endothelial injury. 
NFC findings were classified into three patterns:
•  Early (E) pattern: Few giant capillaries (2–3 per 
field), little capillary haemorrhage (2–3 capillary 
haemorrhages per field) and r latively well pre-
served capillary distribution.
•  Active  (A)  pattern:  Frequent  giant  capillaries 
(5–6  per  field),  frequent  capillary  haemorrhage 
(.5 capillary haemorrhages per field), moderate 
loss of capillaries and avascular areas, and mildly 
disorganized capillary architecture.
•  Late  (L)  pattern:  Irregular  enlargement  of  the 
capillaries  (with  few  or  no  giant  capillaries), 
absence of hemorrhage, severe loss of capillaries 
and large avascular areas (2–3 per field), frequent 
bushy capillaries and severe disorganization of the 
capillaries (4–5 per field).9
Pulmonary function tests
Forced  vital  capacity  (FVC),  forced  expiratory 
  volume  I  (FEV1),  FEV1/FVC%  and  forced  mid-
  expiratory flow rate (FEF25–27) were estimated using 
an automated flowmeter for measuring spirometric 
function. Patients were categorized as follows:
•  A restrictive pattern if the value of FVC as ,75% 
of the predicted value
•  An obstructive pattern if the value of FEV1/FVC% 
was ,75% of the predicted value
•  A small airway affection if the value of FEF25–75 
was ,75% of the predicted value.
Doppler echocardiography
This was performed to calculate the mean pulmonary 
artery pressure to assess pulmonary hypertension.
Colour-flow doppler
This method was used for examination of the renal 
arteries to detect any signs of luminal stenosis with 
calculation of the resistance index (RI). The RI was 
determined from the analysis of the spectral wave-
form as follows:
RI
SF DF
SF
peak
peak
=
− min
Where SFpeak is the peak systolic frequency shift and 
DFmin is the lowest diastolic frequency shift. The RI 
was  calculated  as  a  mean  value  obtained  with  six 
wave forms on the main renal artery and the interolo-
bar and cortical vessels. All reported RI values were 
multiplied by a factor.
Statistical methods
The clinical and laboratory data were transferred to 
IBM cards using an IBM personal computer with the 
statistical software package “Microstat Version 2” to 
obtain the following:
Anti-annexin V antibodies
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(SD), minimum and maximum values range, num-
ber and percentage of qualitative data
•  Analytical statistics: Student’s t-test to compare 
between two independent means, Pearson’s corre-
lation coefficient to find the relationship between 
different variables in the same group, and the Chi-
square test to compare between different groups as 
regards qualitative data.
For  all  tests,  P  .  0.05  was  insignificant  (NS), 
P , 0.05 was significant (S), and P , 0.001 was 
highly  significant  (HS).  All  data  was  graphically 
  represented using Harvard graphics and Power Point 
programs.
Results
This study was conducted on two groups: Group I 
included 20 female SSc patients, ages ranging from 
28 to 56 years with a mean ± SD of 40.2 ± 12.8. 
The disease duration ranged from 3 to 16 years with 
a mean ± SD of 6.7 ± 4.12. Group II included 10 
healthy female subjects as controls, ages ranging from 
26 to 55 years with a mean ± SD of 41.4 ± 11.17. For 
all patients, the parameters for assessing the disease 
activity index were estimated individually for each 
Table 1. Comparison between group I and II as regards laboratory data.
Data Group I 
Mean ± sD 
N = 20
Group II 
Mean ± sD 
N = 10
P Significance
ESR mm/hr   27.3 ± 20.11   9.4 ± 4.07 ,0.001 HS
Hb% gm/dL   11.18 ± 1.38 12.7 ± 0.44 .0.05 NS
RBCs 106/mm3   4.86 ± 0.5   5.1 ± 1.15 .0.05 NS
WBCs 103/mm3   8.21 ± 3.33 8.17 ± 1.56 .0.05 NS
Platlets 103/mm3 261.9 ± 21.13  211 ± 13.4 .0.05 NS
Blood urea nitrogen mg/dL 20.35 ± 8.53 20.1 ± 5.5 .0.05 NS
Creatinine mg/dL   0.79 ± 0.12 0.71 ± 0.10 .0.05 NS
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Figure 1. The frequency of the clinical data of the SSc patients.
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Figure 2. Frequency of immunological markers in Group I.
Table 3. Comparison between anti-annexin V in Groups Ia and Ib.
parameter Group Ia Mean ± sD Group Ib Mean ± sD P Significance
Anti-annexin V(AU/mL) 81.03 ± 21.44 73.94 ± 13.5 .0.05 NS
Table 2. Comparison between anti-annexin V in Groups I and II.
parameter Group I Mean ± sD Group II Mean ± sD P Significance
Anti-annexin V(AU/mL) 83.46 ± 22.44 3.94 ± 4.5 ,0.001 HS
patient. The disease activity index was estimated and 
a score was given for each patient.
Comparing the laboratory data between the patients 
and controls showed a highly significant difference in 
ESR (P , 0.001), being higher in group I (Table 1).
The 20 patients were sub-divided into two groups 
according to AntiScl-70 and ACA antibody positiv-
ity. Group Ia: 12 patients (60%) had diffuse SSc 
(AntiScl-70 positive). Group Ib: 8 patients (40%) 
had limited SSc (ACA positive).
Anti-annexin V antibodies were present in 75% 
of patients (mean 83.46 ± 22.44 AU/mL) vs. 0% in 
the controls (mean 3.94 ± 4.5 AU/mL). Comparison 
between  patients  and  controls  as  regards  levels  of 
anti-annexin V showed a highly significant difference 
(P , 0.001). However, comparison between disease 
subtypes (Groups Ia and Ib) showed no statistical sig-
nificance (P . 0.05) (Tables 2 and 3).
Furthermore, the 20 SSc patients were   re-classified 
into two groups according to the presence of severe 
  ischemic manifestations including digital ulcers, gan-
grene and amputation. Group Is included 11 patients 
(55%)  with  severe  ischemic  manifestations  and 
Group Im included 9 patients (45%) without severe 
ischemic manifestations. Comparison of anti-annexin 
V anti    bodies between these groups revealed a statisti-
cally signifi  cant difference (P , 0.05) (Table 4).
NFC was performed for all patients and controls. 
It showed five patients with the early pattern (25%), 
eight (40%) with the active pattern and seven (35%) 
with the late pattern. As regards the data of the con-
trols, all showed an organized pattern. No abnormal 
capillary  loops,  capillary  haemorrhage  or  avascu-
lar areas were detected. Anti-annexin V antibodies 
were negative in the five patients with the early pat-
tern and positive in all patients with the active and 
late  patterns.  On  comparing  titres  of  anti-annexin 
V between patients with active and late patterns, no 
statistical significance could be detected (P . 0.05) 
(Table 5).
Anti-annexin V antibodies
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raphy was done to assess pulmonary artery pressure 
and to evaluate pulmonary hypertension. In the patient 
group, the pulmonary artery pressure ranged from 28 
to 45 mmHg with a mean ± SD of 35.00 ± 6.00 mmHg. 
Pulmonary hypertension was detected in five patients 
(25%). Pulmonary hypertension was not detected in 
any of the controls and their pulmonary artery pres-
sure ranged between 20 and 30 mmHg with a mean 
value of 21.00 ± 5.00 mmHg. Comparing these results 
between patients and controls revealed a statistically 
significant difference (P , 0.05) (Table 6).
Coloured flow Doppler (CFD) of main renal, inter-
lobar  and  cortical  arteries  was  done  for  all  patients 
and controls, and the RI was calculated. Comparison 
between the patients and controls as regards RI values 
of main renal, interlobar and cortical arteries showed a 
statistically significant difference (P , 0.05) (Table 7).
Correlation  studies  between  anti-annexin V  and 
various parameters of the disease were performed. 
There  was  a  significant  positive  correlation  with 
each disease activity score (r = 0.53, P , 0.05), ACL 
(r = 0.79, P , 0.001) and RI of the main renal artery 
(r = 0.42, P , 0.05) (Table 8).
A  receiver—operator  characteristic  curve  (ROC) 
was drawn and analyzed to study the sensitivity and 
specificity of the anti-annexin V titre with its (positive 
and  negative)  predictive  value  and  efficacy  in  dis-
criminating patients with vascular damage from those 
  without. At  a  cut-off  value  of  50 AU/mL,  the  anti-
  annexin V titre can discriminate cases with   vascular 
damage  from  those  without,  with  62.5%  specificity, 
91.7%   sensitivity, a negative predictive value (NPV) of 
83.3%, a positive predictive value (PPV) of 78.6% and 
an efficacy of 80%. At the cut off value of 50 AU/mL: 
true  negative TN  =  5,  false  negative  FN  = 1, false 
  positive  FP  =  3,  true  positive  TP  =  11,  specificity 
62.5%, sensitivity 91.7%, NPV = 83.3%, PPV = 78.6% 
and efficacy = 80%.
Discussion
Systemic  sclerosis  is  an  autoimmune  connective 
  tissue disease associated with vascular damage, which 
can occur early in the course of the disease resulting 
in  decreased  capillary  blood  flow.  Clinically  overt 
symptoms of SSc include RP and fingertip ulcers. 
In addition, various internal organs can be involved, 
predominantly the lung, the kidneys and the heart.10
Table 7. Comparison between patients and controls regarding the RI of the main renal, interlobar and cortical arteries.
Arteries Group I Mean ± sD Group II Mean ± sD P Significance
RI Main renal artery   119.3 ± 32.4 52.33 ± 2.77 ,0.001 HS
RI Interlobar artery   95.1 ± 32.8 51.71 ± 1.14 ,0.05 S
RI Cortical artery 102.25 ± 31.2   50.4 ± 0.15 ,0.05 S
Table 5. Comparison of anti-annexin V between patients with active and late patterns.
parameter Active pattern Mean ± sD Late pattern Mean ± sD P Significance
Anti-annexin V(AU/mL) 71.67 ± 23.9 83.01 ± 20.18 .0.05 NS
Table 6. Comparison between Groups I and II as regards pulmonary artery pressure.
parameter Group I Mean ± sD Group II Mean ± sD P Significance
Pulmonary artery pressure (mmHg) 35.00 ± 6.00 21.00 ± 5.00 ,0.05 S
Table 4. Comparison between Group Is and Im as regards anti-annexin V antibodies.
parameter Group Is Mean ± sD Group Im Mean ± sD P Significance
Anti-annexin V(AU/mL) 82.69 ± 23.34 51.25 ± 23.65 ,0.05 S
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Group I included 20 female SSc patients, 12 with 
diffuse  SSc  (Group  Ia)  and  8  with  limited  SSc 
(Group Ib). Their ages ranged from 28 to 56 years 
with a mean ± SD of 40.2 ± 12.8. The disease dura-
tion ranged from 3 to16 years with a mean ± SD of 
6.7 ± 4.12. Group II included 10 healthy subjects as 
controls; all of them were females aged 26–55 years 
with a mean ± SD of 41.4 ± 11.17.
In this study, RP was the presenting symptom in 
95% of patients included in the study. RP is known 
to be the presenting symptom in 95%–100% of SSc 
patients. Dysphagia and arthalgia are also common 
symptoms  in  SSc.  Digital  ulcers  and  pitting  scars 
were  detected  in  up  to  67%  of  SSc  patients  and 
telangectasia was also frequently recorded.11,12 ANA 
has been detected in 90% of SSc patients. AntiScl-70 
and ACA are critical in differentiating both subtypes 
of SSc. ACL antibodies have been detected in SSc but 
with far less frequency than in other connective tis-
sue disorders such as systemic lupus erythematosus 
and  primary  antiphospholipid  syndrome.  Recently, 
antifibrillin  1,  anti-endothelial  cells,  anti-annexin 
V and anticollagen antibodies have been associated 
with SSc.13
In  this  study,  anti-annexin  V  antibodies  were 
present in 75% of the patients (Group I) and was 
not detected in any of the controls (Group II) (mean 
83.46 ± 22.44 vs. 3.94 ± 4.5 AU/mL). Comparison 
between both groups showed a highly significant sta-
tistical difference (P , 0.001). However, comparison 
of anti-annexin V antibodies in Groups Ia (diffuse) 
and  Ib  (limited)  showed  no  statistical  significance 
(P . 0.05).
To study the relationship of anti-annexin V antibod-
ies with digital ischemia, patients were re-  classified 
into two groups according to the presence of severe 
clinical  manifestations  of  ischemia,  including  pit-
ting scars, digital ulcers, gangrene and amputation. 
Group Is included 11 patients (55%) with severe isch-
emic manifestations; Group Im included 9 patients 
(45%) without severe ischemic manifestations. Com-
parison of anti-annexin V antibodies between these 
groups revealed a statistically significant difference 
(P , 0.05). Furthermore, correlation of anti-annexin 
V titres with the disease activity score in the patient 
group  showed  a  statistically  significant  positive 
  correlation (r = 0.53, P , 0.05).
Similar studies detected anti-annexin V   antibodies 
in 18.2% of SSc patients and 75% of the patients 
showed ischemic manifestations in association with 
anti-annexin V antibodies. This could be explained 
by the fact that digital ischemia may not simply be 
explained due to thrombosis and that anti-annexin V 
antibodies could possibly be related to the pathogen-
esis of digital ischemia in SSc patients.14
In addition, the anti-annexin V antibody titres in this 
study showed a highly significant positive   correlation 
with ACL antibodies (r = 0.79, P , 0.001). Patients with 
antiphospholipid syndrome (APS) have been known to 
have a higher frequency of anti-  annexin V antibodies, 
and thrombotic events have been reported more fre-
quently in patients with positive anti-annexin V anti-
bodies.15 Furthermore, inhibition of annexin V binding 
to negatively charged phospholipids may be an addi-
tional pathogenic mechanism of APS.16
The patterns of SSc was first described by NFC 
in 1981 as enlargement of the capillary loops, loss of 
capillaries, disruption of the orderly appearance of the 
normal capillary bed and capillary haemorrhages.17 
NFC parameters were found to correlate with the dif-
fuse form of SSc, the degree of cutaneous involve-
ment and the presence of AntiScl-70 antibodies.18
Considering  the  SSc  patterns  obvserved  in  this 
study, 5% of patients had the early pattern, 75% had 
the active and 20% had the late pattern.   Anti-annexin 
V antibodies were negative in the 5% of patients with 
the early pattern, and were positive in all patients 
with  the  active  and  late  patterns.  Comparison  of 
anti-annexin  V  antibodies  between  patients  with 
late  and  active  patterns  showed  no  statistical  sig-
nificance (P , 0.05); however, the mean levels of 
anti-annexin V antibodies in patients with the late 
pattern were somewhat higher.
Table 8. Correlation of anti-annexin V with variable   disease 
parameters.
Variables Anti-annexin V
r P s
Disease duration 0.25 .0.05 NS
ESR 0.13 .0.05 NS
Disease activity score 0.53 ,0.05 S
ACL 0.79 ,0.001 HS
RI of the main renal artery 0.42 ,0.05 S
Pulmonary artery pressure 0.21 .0.05 NS
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to assess pulmonary artery pressure and to evaluate 
pulmonary hypertension. In Group I, the pulmonary 
artery pressure ranged from 28 to 45 mmHg with a 
mean ± SD of 35.00 ± 6.00 mmHg. Pulmonary hyper-
tension was detected in five patients (25%). Pulmonary 
hypertension was not detected in any of the controls. 
Comparison between patients and controls revealed 
a significant difference as regards   pulmonary artery 
pressure (P , 0.05). However, correlation of anti-
annexin V antibodies with mean pulmonary artery 
pressure in the patient group was of no statistical sig-
nificance (P . 0.05).
Both  types  of  lung  disease,  namely  pulmonary 
hypertension and restrictive lung disease, have been 
detected  in  SSc.  Vasculopathy  causing  pulmonary 
hypertension typically occurs in SSc.19,20 Although the 
results of echocardiography are accurate and   adequate 
for diagnosing advanced pulmonary   hypertension, it 
cannot be relied upon to exclude pulmonary hyperten-
sion or to be used as a screening test for early cases.21 
On the other hand, screening for   pulmonary hyperten-
sion by Doppler echocardiography enables early detec-
tion of pulmonary hypertension at a mild stage.22
Considering the kidneys, comparison between the 
patients and controls as regards RI values of main 
renal, interlobar and cortical arteries showed a sig-
nificant difference (P , 0.05). RI values tended to 
decrease from the main renal artery to the cortical 
artery.
In similar studies, RI values of renal vessels have 
been found to increase significantly in SSc patients 
compared to controls, and significant reduction of RI 
values between the interlobar and the cortical arter-
ies of patients has been reported, which indicates an 
increased resistance to distal flow to the interlobar 
artery.23 Renal vascular damage studied by CFD in 
SSc patients that are clinically free of nephropathy 
has detected latent and subclinical renal damage in 
these patients.24 Other studies measuring the RI of 
renal and interlobar arteries in SSc patients with and 
without signs of renal involvement detected a signifi-
cant increase in RI values in patients with signs of 
renal involvement as compared to those without.25 
However, in contrast to this study, a recent study on 
44 patients with End stage renal failure indicated that 
circulating  levels  of  anti-annexin  V  microparticles 
were increased compared with 32 healthy subjects, as 
were levels of microparticles derived from endothe-
lial cells, platelets and erythrocytes. However, when 
arterial function was evaluated noninvasively in these 
patients, only endothelial microparticle levels corre-
lated highly with loss of flow-mediated dilation and 
increased aortic pulse wave velocity.26
In this study, all patients had apparently normal kid-
ney functions, yet the significant difference between 
RI values of patients and controls suggests the pres-
ence of subclinical renal involvement in SSc patients, 
which could be due to a vasculitic process, and may 
progress rapidly to SSc renal crisis or renal failure. 
This  puts  more  stress  on  the  importance  of  early 
detection of renal vascular impairment in SSc. In this 
study, a significant positive correlation was detected 
between the level of anti-annexin V   antibodies and 
RI of the main renal artery (r = 0.42, P , 0.05), 
further    suggesting  the  association  of  anti-annexin 
V antibodies with renovascular damage in SSc and 
thus highlighting the value of its early detection in the 
follow-up of scleroderma patients.
In conclusion, SSc is associated with microvas-
cular  and  macrovascular  organ  damage,  especially 
in  the  pulmonary  and  renal  arteries.  Anti-annexin 
V  antibodies  are  detected  in  SSc,  with  increased 
expression in patients with ischemic manifestations. 
Anti-annexin V antibodies correlate positively with 
the disease activity score, ACL antibodies and RI of 
the main renal artery, and could serve as a sensitive 
predictor of vascular damage in SSc.
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